RNAi report models and quantifies the hype (for those who pony up for the report):
Cheers,
Thomas
Research and Markets: RNAi - The Hottest Technology In Biotechnology
DUBLIN, Ireland, Apr 22, 2004 (BUSINESS WIRE) -- Research and Markets (http://www.researchandmarkets.com) has announced the addition of RNAi 2004: Strategic Opportunities to their offering.
RNAi is the hottest technology in biotechnology. It has the potential to revolutionize biology research and drug target discovery by evolving genomics from inferring correlation to determining causation. It has the potential to widen the bottleneck of putative drug targets awaiting validation by rapidly and cost-effectively determining function. It even has the potential to serve as a broad-based platform for developing targeted therapeutics against a wide range of diseases. As a result of this potential, commercial opportunities abound. But success in this rapidly evolving and highly competitive market requires intelligence.
This report provides a detailed market analysis based on a thorough investigation of technologies, applications, intellectual property, unmet needs and trends. The report includes interviews with experts, evaluations of leading companies, qualitative and quantitative market models across multiple segments of the RNAi value chain, and strategic recommendations for capitalizing on specific opportunities.
Unlike other descriptive reports, RNAi 2004: Strategic Opportunities has focused on the strategic opportunities that are emerging in RNAi, clearly defining the market segments of the RNAi value chain and mapping the qualitative and quantitative opportunity within key segments. The authors are unaware of other reports that offer this depth as well as strategic focus. Indeed, this report provides a number of strategies of value for potential entrants into this marketplace.
The quantitative market models presented in this report address three segments in RNAi space:
1. Synthesis and Validation market for siRNAs
This model describes the creation opportunity for producing and validating siRNAs (specifically capable of knocking-down a given gene in vivo)--the availability of validated siRNAs across a large number of different genes is a key unmet need. The model quantitates the market opportunity in this segment.
2. siRNA Delivery
Delivery of the siRNA to cells is an important problem for which no optimal solution exists. Vendors are seeking to retool their existing product offerings for use in RNAi, but the need for better technology and products exists. This space is modelled quantitatively and figures are presented for how big this market could become.
3. Detection and Analysis of the Knockdown Event
This is a key area of opportunity where vendors can offer new solutions. We present the current state of the art, discuss reasons why this is inadequate and present a quantitative model forecasting how big this market could become.
In addition to the quantitative analyses, the report is full of qualitative trends and drivers that give the reader an understanding of the RNAi landscape. These trends and drivers have been derived from industry analyses, interviews with end-users, and current vendors. Transcripts of primary interviews with key researchers in RNAi have been reprinted verbatim in the report.
Profiles of the relevant companies in RNAi contain SWOT analyses that serve to illustrate the market position of a given company in the space. The report written in PowerPoint, to allow individual slides to be used in business plans and presentations without need for re-work or any significant modification.
Detailed Company Evaluations are provided for
- Akceli, Inc.
- Alnylam Pharmaceuticals, Inc.
- Ambion, Inc.
- BD Biosciences Clontech
- Dharmacon, Inc.
- Imgenex Corporation
- Mirus Corporation
- Promega Corporation
- Qiagen N.V.
- Sequitur, Inc. (InVitrogen)
- Sirna Therapeutics, Inc.
- Akceli, Inc.
- Alnylam Pharmaceuticals, Inc.
- Ambion, Inc.
- BD Biosciences Clontech
- Dharmacon, Inc.
- Imgenex Corporation
- Mirus Corporation
- Promega Corporation
- Qiagen N.V.
- Sequitur, Inc. (InVitrogen)
- Sirna Therapeutics, Inc.
For more information visit researchandmarkets.com
SOURCE: Research and Markets Ltd. |
